{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:49:54Z","timestamp":1785336594708,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.12.010","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:36:21Z","timestamp":1517618181000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Induction Therapy With Thymoglobulin in AB0-Incompatible Kidney Transplantation"],"prefix":"10.1016","volume":"50","author":[{"given":"A.L.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lopau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.12.010_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-6143.2004.00653.x","article-title":"AB0 incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab","volume":"5","author":"Tyden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/01.tp.0000262570.18117.55","article-title":"Implementation of a protocol for ABO-incompatible kidney transplantation\u2014a three-center experience with 60 consecutive transplantations","volume":"83","author":"Tyd\u00e9n","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00007890-199510150-00023","article-title":"Prolonged action of a chimeric interleukin-2 receptor (CD 25) monoclonal antibody used in cadaveric renal transplantation","volume":"60","author":"Amlot","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiinterleukin 2 receptor monoclonal antibody","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of cellular rejection in renal allograft recipients","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2017.12.010_bib6","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2017.12.010_bib7","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1093\/ndt\/gfq229","article-title":"Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis","volume":"25","author":"Wilpert","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ndt\/gfn478","article-title":"ABO blood group\u2013incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies","volume":"24","author":"Oettl","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib9","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1681\/ASN.2015080848","article-title":"Memory CD4 T cells induce antibody-mediated rejection of renal allografts","volume":"27","author":"Gorbacheva","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2017.12.010_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.transproceed.2004.03.084","article-title":"Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies","volume":"36","author":"Castro","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.010_bib13","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1600-6143.2007.01860.x","article-title":"Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation","volume":"7","author":"Patlolla","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/tid.12408","article-title":"Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome","volume":"17","author":"Viot","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.010_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2362.2011.02490.x","article-title":"Long-term outcome of ATG vs basiliximab induction","volume":"41","author":"Ulrich","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.transproceed.2017.12.010_bib16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/tri.12629","article-title":"Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?","volume":"28","author":"Fehr","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.010_bib17","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/TP.0b013e3181726849","article-title":"ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up","volume":"85","author":"Genberg","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1152\/ajprenal.00317.2015","article-title":"Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies","volume":"309","author":"Erdbr\u00fcgger","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.transproceed.2017.12.010_bib19","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/ndt\/gfr215","article-title":"Increase of infectious complications in ABO-incompatible kidney transplant recipients\u2014a single centre experience","volume":"26","author":"Habicht","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-0012.2007.00700.x","article-title":"Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients","volume":"21","author":"Grim","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.transproceed.2017.12.010_bib22","unstructured":"Talotta R, Atzeni F, Batticciotto A, Benucci M, Bongiovanni S, Sarzi-Puttini P. Biological agents in rheumatoid arthritis: a cross-link between immune tolerance and immune surveillance. Curr Rheumatol Rev. Published online December 30,\u00a02016."},{"key":"10.1016\/j.transproceed.2017.12.010_bib23","first-page":"37","article-title":"Overview of safety of nonbiologic and biologic DMARDs","volume":"51","author":"Solez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.transproceed.2017.12.010_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib25","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.humpath.2005.08.009","article-title":"Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods","volume":"36","author":"Drachenberg","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.transproceed.2017.12.010_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal transplant recipients","volume":"347","author":"Hirsch","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2017.12.010_bib27","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.transproceed.2008.08.082","article-title":"Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors","volume":"40","author":"Martinez","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.010_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-012-1727-2","article-title":"Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study","volume":"32","author":"Green","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.010_bib29","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.transproceed.2012.10.047","article-title":"Infectious complications in the first year post renal transplantation","volume":"45","author":"Kosmadakis","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.010_bib30","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.transproceed.2008.08.130","article-title":"Long-term efficacy of induction therapy with antiinterleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation","volume":"40","author":"Taber","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.010_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6002\/ect.2012.0103","article-title":"Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function","volume":"11","author":"Chen","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2017.12.010_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/TP.0b013e318245b2af","article-title":"Outcomes of ABO-incompatible kidney transplantation in the United States","volume":"93","author":"Montgomery","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.010_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-6143.2007.02036.x","article-title":"Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation","volume":"8","author":"Setoguchi","year":"2008","journal-title":"Am J Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T23:06:12Z","timestamp":1719788772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308667"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.010","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Induction Therapy With Thymoglobulin in AB0-Incompatible Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}